The Performance of Nesfatin-1 in Distinguishing Irritable Bowel Syndrome Presenting Predominantly with Diarrhea from Celiac Disease
dc.contributor.author | Karatay, Eylem | |
dc.contributor.author | Gül-Utku, Özlem | |
dc.contributor.author | Aksoy, Neval | |
dc.date.accessioned | 2021-01-14T18:11:02Z | |
dc.date.available | 2021-01-14T18:11:02Z | |
dc.date.issued | 2020 | |
dc.department | KKÜ | |
dc.description.abstract | Background: We hypothesized that nesfatin-1, an anti-inflammatory peptide, could be used as a non-invasive diagnostic tool in the identification of celiac disease (CD) and irritable bowel syndrome presenting predominantly with diarrhea (IBS-D). Methods: Thirty-five patients with IBS-D who met the Rome III criteria, 28 patients with celiac disease who met the diagnostic criteria of the Marsh-Oberhuber classification, and 30 age- and gender-matched healthy controls were included in this cross-sectional study. All subjects responded to the IBS Severity Scoring System (IBS-SSS) questionnaire that was used to determine pain severity, pain frequency, bloating, dissatisfaction with bowel habits, and life interference. Results: Nesfatin-1 levels were significantly higher in the CD group compared to the IBS-D group and healthy controls. Nesfatin-1 was also higher in the IBS-D group compared to controls. Nesfatin-1 levels were correlated with IBS-SSS (r = 0.884, p < 0.001), severity of abdominal pain and discomfort (r = 0.644, p < 0.001), and C-reactive protein concentrations (r = 0.303, p = 0.004). ROC curve analysis demonstrated that a cutoff value of > 98.1 pg/mL for nesfatin-1 could discriminate subjects with CD from those with IBS-D and also healthy controls with a sensitivity of 82% and a specificity of 80%. Conclusions: The results of this study show that subjects with CD have higher nesfatin-1 levels compared to those with IBS-D or to the healthy controls. Moreover, nesfatin-1 can discriminate subjects with CD from those with IBS-D and also healthy controls, with high sensitivity and specificity. Further studies with histopathological evaluation are required to clearly address the role of nesfatin-1 in the diagnosis of CD. | en_US |
dc.identifier.citation | closedAccess | en_US |
dc.identifier.doi | 10.7754/Clin.Lab.2020.191215 | |
dc.identifier.endpage | 455 | en_US |
dc.identifier.issn | 1433-6510 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | 32162872 | |
dc.identifier.scopus | 2-s2.0-85081917157 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 449 | en_US |
dc.identifier.uri | https://doi.org/10.7754/Clin.Lab.2020.191215 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12587/12861 | |
dc.identifier.volume | 66 | en_US |
dc.identifier.wos | WOS:000545455100028 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | |
dc.publisher | CLIN LAB PUBL | en_US |
dc.relation.ispartof | CLINICAL LABORATORY | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | irritable bowel syndrome | en_US |
dc.subject | celiac disease | en_US |
dc.subject | nesfatin-1 | en_US |
dc.subject | inflammation | en_US |
dc.title | The Performance of Nesfatin-1 in Distinguishing Irritable Bowel Syndrome Presenting Predominantly with Diarrhea from Celiac Disease | en_US |
dc.type | Article |